AI assistant
Sending…
Lexaria Bioscience Corp. — Director's Dealing 2009
Jul 10, 2009
34983_dirs_2009-07-10_2239b699-adc7-49fc-8ea5-4f6aa621faeb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LEXARIA CORP. (LXRP)
CIK: 0001348362
Period of Report: 2009-07-08
Reporting Person: BUNKA CHRISTOPHER (Director, Chairman/President/CEO, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2009-07-10 | Common Shares | P | 1600000 | $0.05 | Acquired | 1988213 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2009-07-10 | Warrants | $0.2 | P | 1600000 | Acquired | 2011-07-10 | Common Shares (1600000) | Indirect |
| 2009-07-08 | Stock Options | $0.2 | P | 18750 | Acquired | 2011-07-20 | Common Shares (18750) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Shares | 215.75 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Warrants | $2.4 | 2009-11-09 | Common Shares (291700) | 291700 | Indirect |
| Stock Options | $0.2 | 2011-04-26 | Common Shares (100000) | 100000 | Direct |
| Stock Options | $0.2 | 2011-07-20 | Common Shares (100000) | 100000 | Direct |
Footnotes
F1: Chris Bunka is the sole owner of CAB Financial Services Ltd.
F2: On July 8, 2009 the exercise price was reduced from $0.80.
F3: On July 8, 2009, the exercise price was chaged from $0.12.
More from Lexaria Bioscience Corp.
Interim / Quarterly Report
2026
Apr 13
Director's Dealing
2026
Mar 18
Delisting Announcement
2026
Feb 6
Regulatory Filings
2026
Jan 28
Declaration of Voting Results & Voting Rights Announcements
2026
Jan 28
Capital/Financing Update
2026
Jan 14
Delisting Announcement
2026
Jan 14
Interim / Quarterly Report
2026
Jan 13
Capital/Financing Update
2025
Dec 29
Regulatory Filings
2025
Dec 19